2018
Director Appointment
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), is pleased to announce the appointment of Sarah Park as an Independent Director, effective from 6 December 2018. [read more]
Pacific Edge Completes $7 Million Placement of New Shares
Pacific Edge Limited (NZX: PEB) (Pacific Edge) advises that it has completed a placement of $7m of new shares under its capital raising announced on 29 November 2018 (Placement). [read more]
Pacific Edge Limited Announces Improved Result and Capital Raising
Pacific Edge has announced an improved half year performance and capital raising to assist the company to progress its commercial objectives. [read more]
Full Suite of Cxbladder Tests Adopted by NZ Public Healthcare Provider Capital & Coast DHB
Pacific Edge signs agreement with Capital & Coast District Health Board, providing access to full suite of Cxbladder products [read more]
Cxbladder Commercial Evaluation by Johns Hopkins Medicine
Cancer diagnostics company, Pacific Edge, advises that Johns Hopkins Medicine has commenced their commercial evaluation of Cxbladder, the company’s non-invasive molecular diagnostic test for the detection and management of bladder cancer, with a number of urologists at the institution. [read more]
Pacific Edge Receives Notification of Cxbladder National CMS Reimbursement Rate in the USA
Cancer diagnostics company, Pacific Edge (NZX: PEB) is pleased to advise that the preliminary national CMS reimbursement rate of US$760 (NZ$ 1,166) has been publicly notified. The national reimbursement rate covers the Cxbladder tests awarded national CPT codes in the USA earlier this year, [read more]
Another Of New Zealand’s Public Healthcare Providers, Hauora Tairawhiti, Adopts Cxbladder
Gisborne’s Hauora Tairāwhiti (Tairāwhiti District Health Board) to Implement Cxbladder Testing for Urology Referrals [read more]
Another New Zealand Public Healthcare Provider Signs Up to Cxbladder
Counties Manukau Health to Adopt Cxbladder Tests for Application Across the Clinical Pathway [read more]
Pacific Edge Attracts US Investment And Undertakes Share Placement
Cancer diagnostics company, Pacific Edge Limited, has accepted an investment offer of NZ$ 2.622 million from Manchester Management Company, LLC (MMC), a US privately owned fund specialising in biotech and life sciences investments. [read more]
David Band To Step Down From Pacific Edge Board
Pacific Edge Limited (NZX:PEB) advises that long serving Director, David Band, has indicated that he will step down from the Board at the upcoming Annual Meeting, to be held in August 2018. [read more]
Pacific Edge Issues Annual Report for 12 Months Ending 31 March 2018
Pacific Edge is pleased to issue its Annual Report for the 12 months ending 31 March 2018. Click the links below to read the report and the Annual Review Shareholder Letter. [read more]
Pacific Edge Limited Preliminary Results for Year Ended 31 March 2018
Results for FY18 reflect increasing test volumes and revenues as more urologists and healthcare organisations adopt Cxbladder into clinical use. [read more]
Pacific Edge Adopts New Accounting Standard and Confirms Forecast
Test numbers and cash flows are in line with expectations and on a like-for-like basis, revenue is in line with forecast [read more]
Pacific Edge Full Year Results to be Announced 29 May 2018
Pacific Edge Limited (NZX:PEB) advises that it intends to announce its full year results for the financial year ended 31 March 2018 on Tuesday 29 May 2018, prior to 10am NZST. [read more]
Request for Director Nominations
Pacific Edge Limited advises that the opening date for Director Nominations is Thursday 10th May 2018 and that the closing date for Director Nominations is Wednesday 11th July 2018. [read more]
Pacific Edge receives approval for new CPT codes from AMA
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), advises that the American Medical Association (AMA) Current Procedural Terminology (CPT®) Editorial Panel has granted Administrative MAAA CPT codes for Pacific Edge's Cxbladder Detect and Cxbladder Monitor tests. [read more]
Pacific Edge ranked number 5 in inaugural Financial Times FT 1000 High Growth Companies Asia-Pacific
Pacific Edge Limited is delighted to have been ranked number 5 in the inaugural Financial Times FT 1000 High Growth Companies Asia-Pacific [read more]
Pacific Edge Signs Contract with MediNcrease Health Plan in US
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB), has entered into an agreement with MediNcrease Health Plans, LLC, a national provider network in the United States, to make Cxbladder available to 5.5 million covered lives through its clients and payers. [read more]
Pacific Edge Signs First Commercial Agreement in Singapore
Cancer diagnostics company, Pacific Edge Limited (NZX:PEB) has reached a commercial agreement with Raffles Diagnostica Pte Ltd to offer its suite of Cxbladder tests in Singapore. [read more]
View our Calendar of Events
We welcome press and media enquiries. For further assistance, please feel free to contact us.